Swiss medical device maker Symetis released 30-day registry findings for its 2nd-generation transcatheter aortic valve implantation systems, touting high procedural success rates and minimal valve leakage.
Results from the SAVI postmarket registry highlighted findings from the 1st 250 patients implanted with Symetis’ Acurate TA TAVI system, which won European regulatory approval in September 2011.
Symetis reported a 98% procedural success rate as well as "a very good safety profile and minimal PV leak rate," according to a press release. All-cause mortality at 30 days was 6.8%, a rate that the company touted as one of the lowest in reported registries for other TAVI systems.
"The Acurate TA has proven to be the most user-friendly and patient-effective transapical TAVI today on the market," Symetis clinical & regulatory affairs vice president said in prepared remarks. "Our TA R&D pipeline will further raise this new standard and expand the TA indication."